Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
that "royalty interest" you describe is not documented anywhere and it contradicts what GTHP filed with the SEC.
So you're asking me to believe YOU, an anonymous poster on a message board, instead of the legal SEC filings of a publicly traded company.
You see how that would be hard for me to do, right?
I think Shenghou gave up contractual rights simply because they couldn't fulfill their part of the contract. That doesn't entitle them to royalty payments or any other kind of payment.
If Shenghou "found SMI" to keep their GTHP agreement alive, they would sub-contract with SMI and keep dealing with GTHP themselves. That didn't happen. SMI is dealing directly with GTHP. Shenghou is not part of that agreement in any way. At least, that's what the SEC filings say. You want me to believe that GTHP is lying in their SEC filings, and without proof, I am not going believe that.
No point in discussing this further unless you want to match the proof I offered from the SEC filings with contradicting proof that there's a legal agreement between Shenghuo and GTHP stipulating that Shenghuo gets a royalty from SMI payments.
I think Synergy was a fraud and Nalepka and Whelan were desperate to believe anything, no matter how implausible.
It didn't really send the PPS up so nobody was damaged, and even if someone wanted to claim damages and file a class action because they bought on that "news," it would be hard to get a lawyer to take that class action case because there was no PR or filing or public statement.
Remember the wound healing company that had a dealing with Synergy? KitoTech? I wonder how they fared. I hope they didn't send product without getting paid first.
https://www.prweb.com/releases/kitotech-medical-inc-signs-agreement-with-synergy-corporation-for-international-distribution-of-their-medical-and-consumer-products-803148643.html
The Synergy Deal wasn't "fake" -- it was just a distribution deal that never happened.
Whelan and Nalepka were desperate for SOMETHING to tell shareholders, so maybe they exaggerated a bit, but really, everyone knew it was just a distribution deal with no guarantees.
Whether they admitted it or not, everyone knew.
You criticize me for not believing the word of an anonymous poster on a message board. Sorry, but that's just how I am. I choose to believe GTHP's filings with the SEC until I see contradicting proof.
(Well, sort of anonymous -- I think we know better, don't we? Who would post insider information from the Conte case other than...... ????)
You insist that "SMI owed GTHP $1 Million" but where is that documented? That would be booked as uncollected debt on the balance sheet. Where in GTHP's filings is this booked?
GTHP owed Shenghou money for loans, so it doesn't surprise me that GTHP paid Shenghuo money when they had it, but where is the contractual agreement that says GTHP is OBLIGATED to pay Shenghuo money when/if SMI makes a payment? That makes no sense. Maybe Faupel and/or Blumberg make this claim but I won't believe that until I see it documented in GTHP's filings with the SEC. That contradicts what they DID say in their filings.
The Conte lawsuit is for a $64,000 loan that is under dispute as to whether it was convertible or not. (Conte signed a contract without reading it -- who would do that? Seems shaky to me but the judge is going to allow the case to go to trial.) That's between Faupel, Blumberg, and Conte. GTHP is not involved.
What you are describing contradicts the description GTHP filed with the SEC in every 10-Q and 10-K and prospectus filed in the past five years.
So either GTHP lied in all their SEC filings and you are now disclosing insider information, which is illegal....
OR
You are confused.
I'm assuming you're disclosing information from the depositions from the Conte case. If you're going to disclose that information, quote the depositions directly. I think the problem here lies in a faulty interpretation of what Faupel and Blumberg actually said.
Those are not undisputed facts -- they are misconceptions on your part, IMO.
What you are describing would be an agreement between SMI and Shenguo. You are describing Shenghuo hiring SMI as a sub-contractor. In that arrangement, SMI would pay Shenghuo directly.
If it were true that "GTHP is obligated to share fees (it receives from SMI) with Shenghou Medical, LLC " then that would be described in GTHP's filings. It is not. You're asking us to believe something that is undocumented simply because you say it's true. Sorry, can't do that.
We understand that you have an axe to grind with Faupel and Blumberg. You must be the guy who is suing them. What do you gain by bashing GTHP on this MB? How does that increase your odds of winning the court case against Faupel and Blumberg?
SMI may have paid GTHP some money but it wasn't much -- if you disagree, name the quarter in which SMI's payments show up on the balance sheet. And that $1 million was part of the agreement between Shenghuo and GTHP, not SMI and GTHP.
GTHP doesn't owe Shenghou any money that is contingent upon SMI making a payment. SMI and Shenghuo are completely independent of each other. Any money paid by SMI to GTHP is the property of GTHP, not the property of Blumfeld or Faupel. If GTHP want to repay Shenghup for some past loans, thry can, but they are not contractually obligated to do so if/when SMI pays anything.
Faupel and Blumberg may or may not have to pay Conte some money but GTHP is not a defendant in Conte's lawsuit.
I understand that you are upset about (and perhaps involved in) the Conte case. Perhaps a different message board would be a better place to complain about that matter.
You've got that all wrong. GTHP doesn't have to give Shenghuo a dime of any SMI payment. Shenghuo and SMI are completely independent of each other. GTHP doesn't owe Shenghuo any royalties or percentages because Shenghuo didn't fulfill their part of the agreement.
EPS and PE for a developmental biotech without earnings..... yeah right.
You can stop the trolling. Everyone here is on to your game.
Homey don't play dat game.
it's above 15 cents NOW.
When did SMI "owe" Guided $1 million? I don't see that on the financial reports. SMI failed to pay Guided money on several occasions but Guided didn't deliver product to SMI so Guided wasn't "owed" $1 million, as far as I can tell.
If SMI owed Guided money and didn'y pay it, Guided would write that off as bad debt. In which quarter did that happen?
And when/why would Faupel have any say in the matter? Cartwright was CEO when SMI replaced Shenghuo Medical as the China distributor and still CEO when SMI re-negotiated the most recent agreement.
Regardless -- it certainly appears that Chinese clinical trials have been completed, and Guided didn't have to pay for it, so if those Chinese researchers publish their results it's a win, even if SMI never pays Guided a red cent.
Why is Erin Sanders "Open to Relocating" at the top of her LinkedIn page, and "willing to relocate" in her LinkedIn profile?
"Open to Relocating" is the tagline for every one of her LinkedIn posts.
As I'm sure you saw in the 11/20 PR, SMI says they've completed those last 12 patients and:
I've exposed FOUR lies you told. Can you reveal ONE lie I told? No, you can't, because I am not a liar.
Do you not see the difference between LYING and expressing a critical opinion?
Yes, I am skeptical of SMI, but I never LIED about them. I'll say something positive about SMI when they pay the $$$ millions they've been promising.
That might actually happen, maybe even in Q4 2023 or Q1 2024, but until it shows up on the balance sheet, I'm not going to falsely praise SMI. They signed many agreements with Guided that had to be re-negotiated when SMI failed to deliver what they promised. That is the documented truth.
You have NEVER said a positive thing about GTHP with EITHER of your aliases.
I have nothing new to add because the company has nothing new to add. When there's something new. I post it. Until then, I'll just keep exposing you for the fraud that you are. If exposing your lies and deceit is a "personal attack" then so be it.
Have a wonderful weekend.
Sorry, am I interfering with your bashing?
Remember post #15344 where you claimed to be ignoring me? Just another lie from you, I see.
Remember when you said that the CEO stole all the money?
Remember when you said the Officers and Directors were fake names and didn't exist?
Remember when you said they'd never start US clinical trials?
Remember when you used two aliases to simulate a conversation?
Obviously DO care about what I and others post because that's all you talk about. That's ALL you care about, apparently. That's a shame because nothing you or I or anyone else says on this MB has any effect on the PPS, so you truly are wasting your time.
If this stock goes to no bid or if the company goes under, it won't be caused by anything said on any message board. The only people reading about BIEL on Message Boards already know everything they need to know about this stock and this company.
It might stagnate to No Bid but Whelan and Staelin don't care. The company's not going under because Staelin and Whelan need to cash out their convertible loans. At some point, they'll do a reverse split and write some PR's timed with the maturity dates of their loans, and they will convert and dump, and existing shareholders will pump the news and shout "thank you, may I please have another."
Luckily, we have YOU watching this.
Pumping this stock is at the expense of others -- you do realize that, right?
BTW I'm not flipping this stock. The last time I bought BIEL was in 2020. Currently, I own the same amount of stock as Richard Staelin. We both own exactly as much of this stock as we think is prudent.
That amount is zero.
The fact that nobody can "contribute current financials" is not a problem, in your opinion?
Do you disagree that the "current state of the company" is disrespectful silence and complete absence of transparency?
Why should someone invest in this company? Give one reason. Or don't you have even one reason?
Yes, Art contributes the past. What are YOU contributing here?
Forbes is legit. Now THERE is something worth promoting.
They list pros and cons, and the only real con is that you might need to wear it 12 hours per day... to which I say, bring it on. I have had back pain on and off for many years, caused by moving furniture for Mayflower in my 20's and basically abusing my back my whole life... I wear a back brace most of the time anyway. I'm sure that anyone with chronic back pain agrees with me.
The problem is that he didn't post this URL:
https://www.top5-usa.com
He posted THIS URL and called it "the Top 5 Actipatch In The US - Black Friday 2023:"
https://www.top5-usa.com/actipatch
And the best choice for "actipatch" is not an actipatch.
I had to explain that?
of COURSE that's all you see.
Blinders will do that.
You don't see the irony? Search this goofy site for the top five ActiPatch devices, and the top two devices it returns are not even ActiPatch?
the "BEST CHOICE" -- #1 -- is a competitor's PEMF device. the #2 devices is a TENS unit. You don't see the irony in that?
I understand what you SAID but I don't understand what you MEAN.
You are describing normal legal MM activity in a thinly traded OTC stock.
the top two aren't ActiPatch.
Do you see that? Of your "top 5 ActiPatch," the top two are not.
They have to report annual results on March 31st to avoid dropping into the Expert Market.
The annual statement doesn't have to break anything down by quarter -- it just has to be a fiscal year EOY report. For that reason, we'll never know what sales were in Q3 or Q4.
The truly incompetent don't know they're incompetent.
It's the reason the BIEL CEO will never "reach out for the correct guidance and help." It's called the Dunning–Kruger effect.
https://en.wikipedia.org/wiki/Dunning%E2%80%93Kruger_effect
And competitors can sell your product too, since you don't have a patent to stop them!
Competitors can order the device from Shenzhen CICD with their own labeling.
https://cicdtech.en.made-in-china.com/
For example, J&J could sell the device under their own brand name without paying BIEL a penny.
Dr. Scholl's could sell their own version of the Smart Insole without paying BIEL a penny.
This MB will never go away. It's not driven by the status of the MYMX ticker.
witness KKUR, SPNG, et al -- tickers that are long gone but the iHub MB lives on.
I'm not going to talk about any stock or company in a positive light if I don't see positives.
That plantar study Hawk found is positive. BIEL needs to make that public by paying for a press release. Staelin talked about R&D in his last communication but BIEL isn't doing much R&D on their own (if any). They need to publicize independent research like this plantar study.
Not an email to the shareholder newsletter group -- that's just preaching to the choir. The company needs to pay for a press release.
When is that going to happen?
Do you EVER talk about the stock or the company?
Or do you do nothing but mock, ridicule, and complain about others?
Whatever.
Same old tired argument, again and again.
Fine, you win, they don't need no steenkin' patents.
They're going to suddenly start selling the device hand over fist, money will pour in, they'll repay those loans, and then they'll buy back shares and do a FORWARD split.
When? Soon!
What in the world are you talking about?
There was a bid at 0.136$ & an ask at 0.16$ and a trade happened at 0.136$ -- what is your point? A seller dropped to .136 and that is illegal or unethical in your eyes?
Your opinion was only met with patent arguments when we thought BIEL had patents. That is no longer the case.
But my argument has ALWAYS been that the convertible debt never gets paid in cash -- the conversion of the debt is the ONLY way those loans are satisfied.
Might happen, might not. With the patents gone, it now looks like the Whelans and Staelin are SOL and will have to eat that debt.
You think BIEL's plan is to develop new technology, apply for new patents, and get that cleared by the FDA? How would they fund that plan, and why are they dragging their feet? That plan would take YEARS.
"lack of funds" would be a BS excuse because:
* Patent Maintenance fees are minimal, especially for something that important.
* The company had huge revenues coming in at that time (or claimed to, anyway).
Regardless, Staelin would have happily lent that money to the company to protect his investment if he had been aware, IMO. Without patent protection, this company is worth pretty much nothing.
Think about it. Without patent protection, the only way BIEL has value is if they can do something better than anyone else. I can't think of what that might be. Their products have minimal Brand Name recognition -- a competitor could surpass that easily with a marketing campaign.
Yes, the patents have expired.
And it's not because they reached the end of their life. It's because Whelan forgot to pay the maintenance fees.
When patents expire because of nonpayment of maintenance fees, there's a window where you can reinstate them, no questions asked. That window has passed for BIEL's patents. Now, to reinstate the patents, Whelan has to convince the USPTO that it was "unavoidable" (the USPTO's word, not mine) that she let the patents expire.
I'd love to hear her explanation about why it was unavoidable. That happened in 2021 when BIEL was publicly bragging about 400% revenue increases.
Why did you omit the YEAR? That was 2022.
Oct 28, 2022.
Synergy is dead.
Management saying "we will make an official announcement when appropriate" is a typical Whelan bullshit riddle answer. It's Whelan's way of trying to placate investors without saying anything. That Whelan riddle answer is true of every announcement everywhere: as opposed to making an official announcement when it's NOT appropriate?
And Whelan likes to adopt a condescending or aggressive tone when she serves up one of her riddle answers. That's not a tone an experienced CEO would take.
Did you take a look at the volume of those trades?